A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease

NCT04002830

Last updated date
Study Location
All India Institute of Medical Sciences
New Delhi, , , India
Contact
+972-52-6659995

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

+972-52-6659995

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 3 Gaucher Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male or female of any age; however, if female:

- must be using contraception if of childbearing potential or must be surgically sterile

- must not be lactating

2. Diagnosis of Type 3 GD by enzyme and sequence analysis; and confirmed by the Medical Monitor.

3. Splenomegaly at least 5 x multiples of normal (MN).

4. Treatment-naïve.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Eligible subjects may not have any of the following exclusion criteria:


1. Type 2 GD.


2. Presence of myoclonic seizures.


3. At least one allele of:


- N370S (N409S in recent nomenclature)


- R496H (R535H in recent nomenclature)


4. Presence of calcification in heart valves or arteries in echocardiography.


5. Presence of untreated iron, folic acid, vitamin B12 deficiency and/or hypothyroidism.
(Resolved anemia is not an exclusion criterion.)


6. Presence of human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg),
and/or hepatitis C infections.


7. Splenectomy and bone marrow transplantation.


8. Presence of any medical, emotional, behavioural, or psychological condition that in
the judgment of the Investigator would interfere with the subject's compliance with
the requirements of the study.


9. Any other disorder that may interfere with the results of the efficacy endpoints.


10. Pregnancy or breastfeeding.


11. Currently taking another investigational drug for any condition or any therapeutic
drug for Gaucher disease.


12. The subject and/or subject's parent(s) or legal guardian(s) are unable to understand
the nature, scope, and possible consequences of the study.


13. Medical history of any food/drugs allergy.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Type 3 Gaucher DiseaseA Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
NCT04002830
  1. New Delhi,
  2. Jerusalem,
  3. Ankara,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
Official Title  ICMJE A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
Brief Summary This is a multicenter study to assess the safety and efficacy of taliglucerase alfa (60 units/kg) in previously untreated subjects of any age with Type 3 GD. Subjects will receive an infusion of taliglucerase alfa every 2 weeks for 12 months. Subjects who tolerate the infusions well, and who are treated in centers where home therapy is the SOC will be allowed to switch from site to home treatment at the discretion of the PI but after no less than 3 uneventful infusions at the site.
Detailed Description Patients with Type 3 GD exhibit both visceral and neurologic manifestations. In addition to the progressive neurologic involvement, somatic disease manifestations, especially splenomegaly and resulting cytopenia, contribute to significant mortality and morbidity . The effects of enzyme replacement therapy (ERT) on patients with Type 1 GD have been clearly documented and have a beneficial effect on visceral and hematologic disease parameters . It is known that recombinant enzyme does not pass the blood-brain barrier and has no effect on neurologic involvement . Probably due to the rarity of Type 3 GD, information on the somatic effects of ERT is largely limited to case reports or single-center series. There are also few reviews of cohorts but the clinical subtype, age, genotype, ERT dosage, accompanying therapies, and treatment response vary widely among patients in these cohorts. This prospective study aims to objectively evaluate the hematologic and visceral effects of ERT with taliglucerase alfa on a rather clinically and genetically homogenous group of treatment-naïve patients with Type 3 GD . For the purposes of this study, subjects receiving no Gaucher-specific medications for at least 12 months will be considered "untreated". The results of this study are expected to provide a more objective view of the degree of response of this patient type, and potentially create new areas of research.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Type 3 Gaucher disease patients
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Gaucher Disease, Type 3
Intervention  ICMJE Drug: Elelyso
Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
Other Name: Taliglucerase Alfa
Study Arms  ICMJE Experimental: Taliglucerase Alpha
Intravenous infusion of Taligluucerase alfa (Elelyso) in treatment-naive patients with type 3 Gaucher disease
Intervention: Drug: Elelyso
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: June 27, 2019)
15
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 1, 2022
Estimated Primary Completion Date August 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female of any age; however, if female:

    • must be using contraception if of childbearing potential or must be surgically sterile
    • must not be lactating
  2. Diagnosis of Type 3 GD by enzyme and sequence analysis; and confirmed by the Medical Monitor.
  3. Splenomegaly at least 5 x multiples of normal (MN).
  4. Treatment-naïve.

Exclusion Criteria:

Eligible subjects may not have any of the following exclusion criteria:

  1. Type 2 GD.
  2. Presence of myoclonic seizures.
  3. At least one allele of:

    • N370S (N409S in recent nomenclature)
    • R496H (R535H in recent nomenclature)
  4. Presence of calcification in heart valves or arteries in echocardiography.
  5. Presence of untreated iron, folic acid, vitamin B12 deficiency and/or hypothyroidism. (Resolved anemia is not an exclusion criterion.)
  6. Presence of human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), and/or hepatitis C infections.
  7. Splenectomy and bone marrow transplantation.
  8. Presence of any medical, emotional, behavioural, or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.
  9. Any other disorder that may interfere with the results of the efficacy endpoints.
  10. Pregnancy or breastfeeding.
  11. Currently taking another investigational drug for any condition or any therapeutic drug for Gaucher disease.
  12. The subject and/or subject's parent(s) or legal guardian(s) are unable to understand the nature, scope, and possible consequences of the study.
  13. Medical history of any food/drugs allergy.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Majdoleen J Istaiti, B.Sc+972-52-6659995[email protected]
Listed Location Countries  ICMJE India,   Israel,   Turkey
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04002830
Other Study ID Numbers  ICMJE WI224302
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party Ari Zimran, Shaare Zedek Medical Center
Study Sponsor  ICMJE Ari Zimran
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Ari Zimran, Prof.Shaare Zedek Medical Center
PRS Account Shaare Zedek Medical Center
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP